Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Saylor’s $80B Bitcoin Bet Rivals Tech Giants’ Treasuries

Saylor’s $80B Bitcoin Bet Rivals Tech Giants’ Treasuries

CoinomediaCoinomedia2025/10/08 10:57
By:Ava NakamuraAva Nakamura

Michael Saylor’s Bitcoin strategy now holds $80B in BTC, placing MicroStrategy among the top 5 corporate treasuries in the S&P 500.Top 5 Treasury in the S&P 500Outpacing Traditional Strategies

  • MicroStrategy now holds $80B worth of Bitcoin.
  • It’s the 5th largest corporate treasury in the S&P 500.
  • Its BTC reserves rival those of Amazon and Microsoft.

Michael Saylor’s aggressive Bitcoin strategy continues to pay off in a big way. MicroStrategy, the company he co-founded and led as CEO until 2022, now holds a staggering $80 billion in Bitcoin, solidifying its place as one of the largest corporate treasuries in the United States.

What started as a bold experiment has become one of the most successful corporate Bitcoin strategies to date. With Bitcoin’s recent surge in value, MicroStrategy’s holdings have ballooned to levels that rival the cash reserves of tech giants like Amazon, Google, and Microsoft.

Top 5 Treasury in the S&P 500

According to the latest data, MicroStrategy’s Bitcoin treasury now ranks 5th among all companies in the S&P 500—a position usually dominated by companies with vast cash reserves. Saylor’s long-term conviction in Bitcoin has turned the company into a de facto Bitcoin ETF, without being one.

While many companies choose to keep their treasuries in fiat or government bonds, MicroStrategy went all in on Bitcoin. This unorthodox move was heavily criticized in the beginning, but today, it’s proving to be a forward-thinking strategy that’s paying off big.

🔥 BULLISH: Michael Saylor's Strategy now holds $80B in $BTC , nearing Amazon, Google and Microsoft's cash reserves, ranking the 5th largest corporate treasury among S&P 500 companies. pic.twitter.com/XrpMQ2tRvb

— Cointelegraph (@Cointelegraph) October 8, 2025

Outpacing Traditional Strategies

By converting a large portion of its cash into Bitcoin, MicroStrategy has outperformed many traditional corporate treasury strategies. Bitcoin’s rise in value has elevated the company’s financial standing significantly, drawing attention from both Wall Street and the crypto community.

Michael Saylor has consistently maintained that Bitcoin is the ultimate store of value, often comparing it to digital gold. His long-term vision, backed by consistent accumulation, has not only boosted MicroStrategy’s net worth but also inspired other companies to consider Bitcoin as part of their treasury strategy.

0
1

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26